The role of the miR-200 family in epithelial-mesenchymal transition in colorectal cancer: a systematic review.
Stephen J O'BrienJane V CarterJames F BurtonBrent G OxfordMiranda N SchmidtJacob C HallionSusan GalandiukPublished in: International journal of cancer (2018)
Colorectal cancer (CRC) is associated with significant morbidity and mortality as many patients are diagnosed with advanced stage disease. MicroRNAs are small, noncoding RNA molecules that have a major role in gene expression regulation and are dysregulated in CRC. The miR-200 family is involved in epithelial-mesenchymal transition (EMT). This systematic review describes the roles of the miR-200 family in EMT in CRC. A search of electronic databases (PubMed and Embase) was conducted between January 2000 and July 2017. Both in vitro and human studies reporting on the miR-200 family and CRC were included. Studies describing molecular pathways and the role of the miR-200 family in the diagnostic and therapeutic management of CRC were analyzed. Thirty-four studies (22 in vitro and 18 human studies) were included. miR-200 family expression is regulated epigenetically and via transcriptional factor regulation. In vitro studies show that transfection of miR-200 family members into chemo-resistant colon cancer cell lines results in improved chemo-sensitivity and epithelial phenotype restoration. There is intra-tumoral variability in the tissue expression of miR-200 family members with decreased expression at the invasive front. Clinical studies in CRC patients have shown decreased primary tumor tissue expression of miR-429, miR-200a and miR-200c may be associated with worse survival. Conversely, increased blood levels of miR-141, miR-200a and miR-200c may be associated with worse outcomes. The miR-200 family has a central role in EMT. The miR200 family has potential for both prognostic and therapeutic management of CRC.
Keyphrases
- cell proliferation
- long non coding rna
- long noncoding rna
- poor prognosis
- epithelial mesenchymal transition
- gene expression
- systematic review
- end stage renal disease
- emergency department
- endothelial cells
- randomized controlled trial
- squamous cell carcinoma
- machine learning
- transcription factor
- chronic kidney disease
- drug delivery
- climate change
- newly diagnosed
- transforming growth factor
- prognostic factors
- binding protein
- skeletal muscle
- combination therapy